Biohaven Ltd. (NYSE:BHVN), a company focusing on neurological, psychiatric, and cancer-related treatments, was highlighted by Jim Cramer during the lightning round. Cramer disclosed his personal deal with Biohaven and expressed surprise at the stock’s low value. Despite potential, other AI stocks may offer better investment opportunities. If interested in undervalued AI stocks, check out the best short-term AI stock in a free report. BHVN continues to be a topic of discussion among investors and analysts.

Read more at Yahoo Finance: “The Stock Seems Very Low to Me”